Your browser doesn't support javascript.
loading
Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Ward, Thomas; Webster, Samantha; Mishina, Sari; McEwan, Phil; Wygant, Gail; Wang, Feng.
Afiliação
  • Ward T; Health Economics and Outcomes Research, Ltd., Cardiff, UK.
  • Webster S; Health Economics and Outcomes Research, Ltd., Cardiff, UK. Electronic address: samantha.webster@heor.co.uk.
  • Mishina S; Health Economics and Outcomes Research, Bristol-Myers Squibb KK, Tokyo, Japan.
  • McEwan P; Health Economics and Outcomes Research, Ltd., Cardiff, UK; Swansea Centre for Health Economics, School of Human and Health Sciences, Swansea University, Swansea, UK.
  • Wygant G; World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals, Ltd., Princeton, NJ, USA.
  • Wang F; World Wide Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals, Ltd., Princeton, NJ, USA.
Value Health Reg Issues ; 12: 1-6, 2017 May.
Article em En | MEDLINE | ID: mdl-28648305
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Inibidores de Proteases / Sulfonamidas / Uridina Monofosfato / Benzimidazóis / Análise Custo-Benefício / Hepatite C Crônica / Fluorenos / Imidazóis / Isoquinolinas Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Inibidores de Proteases / Sulfonamidas / Uridina Monofosfato / Benzimidazóis / Análise Custo-Benefício / Hepatite C Crônica / Fluorenos / Imidazóis / Isoquinolinas Idioma: En Ano de publicação: 2017 Tipo de documento: Article